Study of Efficacy and Safety of Investigational Treatment in Patients With Hidradenitis Suppurativa
Study of Efficacy and Safety of Investigational Treatment in Patients With Hidradenitis Suppurativa
ClinicalTrials.gov ID: NCT04989517
Sponsor: Azora Therapeutics Australia Pty Ltd
Information provided by: Azora Therapeutics Inc. (Azora Therapeutics Australia Pty Ltd) (Responsible Party)
Last Update Posted: 2024-03-15
Brief Summary:
This is a randomized, double-blind, placebo-controlled, parallel-group phase 1b study to evaluate AT193 in approximately 44 participants with HS. The treatment period will be 8 weeks followed by a 2-week nontreatment follow-up. The primary objective of this study is to evaluate the safety and tolerability of AT193. The secondary objectives of this study are to evaluate the preliminary efficacy in the treatment of HS.
Official Title:
A Randomized, Double-Blind, Placebo-Controlled Phase 1b Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of AT193 in the Treatment of Patients With Hidradenitis Suppurativa
Intervention / Treatment:
- Drug: AT193
| Category | Value |
|---|---|
| Study Start (Actual) | 2021-11-23 |
| Primary Completion (Actual) | 2023-03-15 |
| Study Completion (Actual) | 2023-03-15 |
| Enrollment (Actual) | 49 |
| Study Type | Interventional |
| Phase | Phase 1 |
| Other Study ID Numbers |
HS01
|